Eribulin, a simplified ketone analog of the tubulin inhibitor halichondrin B, for the potential treatment of cancer.
Eribulin, a simplified ketone analog of the tubulin inhibitor halichondrin B, for the potential treatment of cancer.
复制标题
DOI：
--
复制
发表时间：
2007-12
影响因子：
--
通讯作者：
S. Newman
中科院分区：
文献类型：
--
作者：
S. Newman
艾日布林是微管蛋白抑制剂软海绵素B的简化合成大环酮类似物，用于潜在的癌症治疗。在美国和欧洲，针对乳腺癌患者的III期试验正在进行中。艾日布林目前处于NSCLC和软组织肉瘤以及胰腺癌、前列腺癌、卵巢癌、输卵管癌、腹膜癌和头颈癌的II期试验中，以及尿路上皮癌的I/II期试验中。
Eisai Co Ltd is developing eribulin, a simplified synthetic macrocyclic ketone analog of the tubulin inhibitor halichondrin B, for the potential treatment of cancer. Phase III trials are underway in the US and Europe for patients with breast cancer. Eribulin is currently in phase II trials for NSCLC and soft tissue sarcoma, and pancreatic, prostate, ovarian, fallopian tube, peritoneal and head and neck cancer, and phase I/II trials for urothelial cancers.